end-stage knee joint disease
Conditions
Interventions
intravenous group:The intravenous group received 20mg/kg of TXA administered intravenously 30 minutes before incising skin and the same dose and administration 12 hours postoperatively.
topical group:The topical group received 3.0g TXA (total 60ml solution) administered intra-articularly after subcutaneous tissue was sutured.
oral group:The oral group received 20mg/kg of TXA administered orally 2 hours preoperatively and the same dose and administration 12 hours postoperatively.
blank group:No TXA was used for the blank group.
Sponsors
Orthopeadic Department, West China hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
47 Years to 84 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were comprised of osteoarthritis(OA) or rheumatoid arthritis(RA) of knee joint; primary unilateral TKA; at least a 3-week follow-up; normal clotting mechanism and effectively controlled medical diseases(diabetes mellitus and hypertension, etc.).
Exclusion criteria
Exclusion criteria: Exclusion criteria included bilateral TKA once time; revision of TKA; severe hepatic, renal, cardiovascular or respiratory diseases; coagulopathy and bleeding disorders, as well as those currently receiving anticoagulant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Haemoglobin loss;Drainage volume;Transfusion units;Additional cost; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tourniquet time;Thromboembolic complications;Wound healing; | — |
Countries
China
Contacts
Public ContactXianlong Zhang
the Sixth People's Hospital of Shanghai
Outcome results
None listed